Mei Ri Jing Ji Xin Wen·2025-08-11 23:33Group 1 - Beijing Beida Pharmaceutical's subsidiary, Beijing Beida Medicine, has suspended its main business since June 2025 due to the termination of a long-term service contract with Peking University International Hospital [1] - The termination reflects the subsidiary's weak business structure and inability to diversify its client base, which may lead to operational sustainability issues and potential personnel adjustments [1] - The parent company may experience short-term performance impacts as a result of this development [1] Group 2 - Huaxi Biological's fermentation-derived chondroitin sodium has successfully completed the main document registration with the National Medical Products Administration, marking it as the first compliant fermentation-derived chondroitin sodium in China [2] - This new pharmaceutical-grade raw material can be applied in Class II and III medical devices, potentially expanding the company's raw material business applications and serving as a new growth point for performance [2] - Future market expansion and downstream customer integration will be critical for the commercial success of this product [2] Group 3 - Tongrentang announced a change in leadership, with the resignation of Chairman Di Shubing and the election of Zhang Zhaohua as the new chairman [3] - This leadership change is part of normal internal rotation and may indicate a strategic management strengthening and business development push for the company [3] Group 4 - *ST Wuzhong has initiated arbitration against Regen Biotech, Inc. for breach of contract, with the Shenzhen International Arbitration Court accepting the case [4] - The arbitration seeks to confirm the validity of the exclusive agency agreement and may involve a preliminary claim for damages amounting to RMB 1.6 billion, covering various losses [4] - The outcome of this arbitration could significantly impact *ST Wuzhong's operational pressure and stock price, depending on the ruling [4] Group 5 - Rongchang Bio's RC148 has been proposed for inclusion in the breakthrough therapy designation program for treating advanced or metastatic non-small cell lung cancer [5] - This PD-1/VEGF dual antibody is the fourth of its kind to receive such designation, following competitors like Kangfang Biotech and Promis [5] - The competitive landscape for multi-target dual antibodies is intensifying, and Rongchang's progress may further drive technological advancements in the industry [5]